A glucagon-like peptide-1 is easy to forget on a surgery form.
Do not forget it.
Glucagon-like peptide-1 medicines and tirzepatide can slow stomach emptying. A 2024 review says food or fluid left in the stomach is found more often with glucagon-like peptide-1 medicines at endoscopy or anesthesia. Aspiration itself is rare, and evidence for exact hold times remains limited. [1]
That is why the anesthesia team needs to know.
These are prescription medicines. The prescriber and anesthesia team should both know the last dose date.
Residual stomach contents are the practical issue
In a cross-sectional study of 124 fasted patients before elective anesthesia, increased stomach contents were found in 56% of glucagon-like peptide-1 users versus 19% of nonusers. After adjustment, glucagon-like peptide-1 use was linked with a higher prevalence of increased stomach contents. [2]
This does not mean every glucagon-like peptide-1 patient is unsafe for surgery.
It means fasting rules, symptoms, procedure timing, and medication timing need a real plan.
Guidance is becoming individualized
Official surgery guidance has shifted away from simple one-size-fits-all stopping rules. Multi-society guidance emphasizes aspiration risk, stomach symptoms, dose escalation, diabetes control, and procedure needs. [3]
For a woman after menopause, the practical screen is simple: tell the prescriber and anesthesia team about the exact product, dose, last dose date, gastrointestinal symptoms, constipation, reflux, diabetes medicines, and procedure date.
Older 2023 ASA consensus guidance used a more conservative hold-day frame. [4] That history matters because patients may find conflicting advice online. The safer move is to ask the team using current local protocol, not to follow an old generic rule silently.
The most useful answer is usually not "glucagon-like peptide-1 or no glucagon-like peptide-1." It is a risk-stratified plan. A stable patient on a maintenance dose with no nausea, vomiting, reflux, bloating, or constipation may be managed differently from a patient who just increased the dose and feels full after a few bites. Diabetes also changes the tradeoff, because holding therapy can affect glucose. That is why the medication list, last injection or pill date, symptoms, and procedure type all belong in the same conversation.
Red-flag table for procedure planning
| Situation | Why it changes the plan |
|---|---|
| Dose is being escalated | gastrointestinal symptoms and delayed emptying may be more likely during escalation. |
| Nausea, vomiting, bloating, reflux, or severe constipation | Symptoms can signal higher residual-stomach-content risk. |
| Diabetes medications are involved | Holding a glucagon-like peptide-1 may affect glucose planning and should not be improvised. |
| Colonoscopy, endoscopy, deep sedation, or general anesthesia is planned | Fasting, bowel prep, and aspiration precautions may differ by procedure. |
| Prior gastroparesis or severe reflux | The anesthesia team may need a higher-risk pathway. |
| Patient does not know the last dose date | The team cannot make a clean risk decision without dose timing. |
Evidence limits and who this fits
The evidence is limited for one universal glucagon-like peptide-1 hold rule before every procedure. Current guidance is more individualized: aspiration risk, delayed gastric-emptying symptoms, dose escalation, diabetes control, and procedure type all change the plan. [1] [2] [3]
This page fits patients using glucagon-like peptide-1 or tirzepatide who have surgery, endoscopy, colonoscopy, or deep sedation coming up. It is a poor fit for hiding the medication, guessing a hold time, ignoring vomiting or severe reflux, or restarting without a post-procedure plan.
Decision checkpoint: what changes the plan
| Signal | Why it changes the plan | What to do next |
|---|---|---|
| Dose escalation is causing worsening nausea, constipation, reflux, or low intake | Titration is a safety and adherence decision, not just a calendar event. | Review dose timing, hydration, bowel plan, nutrition, and whether escalation should wait. |
| Severe abdominal pain, repeated vomiting, dehydration, or gallbladder-type pain | Labels treat pancreatitis, gallbladder disease, kidney injury from volume depletion, and severe gastrointestinal reactions as warning-level issues. | Ask for clinician instructions rather than self-adjusting or pushing through. |
| Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 | glucagon-like peptide-1 and dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 labels include boxed-warning and contraindication language for this history. | Do not treat eligibility as a weight-only decision. |
| Diabetes medicines, blood-pressure medicines, or procedure plans are involved | Appetite, glucose, fluid status, delayed gastric emptying, and anesthesia planning can interact. | Put the medication list, last dose date, symptoms, and procedure timing in one plan. |
| A compounded, research-use, or self-measured product is being considered | Product source and dose accuracy become part of the risk, not a minor logistics issue. | Anchor the discussion to approved labels and clinician monitoring. |
Evidence boundary
For a planned surgery, the point is not simply that glucagon-like peptide-1 medicines can work. What counts for more, once anesthesia and aspiration risk is on the table, is the gap between trial efficacy and patient-specific fit. For the pre-operative window, the approved labels already define contraindications, warnings, escalation, product-specific adverse reactions, pregnancy cautions, hypoglycemia risk with diabetes medicines, kidney-dehydration monitoring, gallbladder concerns, pancreatitis symptoms, and procedure disclosure. [5] [6]
It matters especially after menopause for a planned surgery, when weight loss can overlap with constipation, reflux, gallbladder history, kidney vulnerability during dehydration, muscle and bone preservation, sleep apnea, diabetes prevention, and medication changes. Around anesthesia and aspiration risk, a page that skips those tradeoffs may rank for a query, yet it does not help the reader make a safer decision.
For the pre-operative window, the evidence earns its keep by separating three questions: whether the drug class fits, whether this specific product and dose path fit, and whether current symptoms mean the plan needs to slow down or change. Around a planned surgery, outcome trials and standards of care can frame the metabolic context, yet they do not cancel label-based warnings or individualized screening. [6]
What this changes at the visit
For a visit about anesthesia and aspiration risk, come with the exact product name, dose, last dose date, dose-escalation stage, bowel pattern, nausea or reflux severity, hydration status, protein intake, diabetes medicines, kidney history, gallbladder history, thyroid-cancer family history, surgery plans, and any compounded-product details. When the pre-operative window is the concern, a clinician does not need a flawless daily log. Around a planned surgery, a clinician needs enough signal to judge whether this calls for routine monitoring, a slower titration, a medication switch, or a red-flag evaluation.
What to ask a clinician
Ask:
- Should I continue, hold, or adjust my glucagon-like peptide-1 before this procedure under your current protocol?
- Does my dose-escalation timing change the plan?
- Do my nausea, reflux, constipation, bloating, or vomiting symptoms raise aspiration-risk concern?
- If I have diabetes or prediabetes, how should glucose be managed if the medication is held?
- Should I use a liquid diet, different fasting plan, gastric ultrasound, delay, or other precaution?
- When should I restart after the procedure?
Bottom line
Do not hide a glucagon-like peptide-1 before surgery, colonoscopy, endoscopy, or deep sedation.
The safe move is early disclosure. The prescriber and anesthesia team can decide whether to continue, hold, adjust diet, delay the procedure, use ultrasound, or take other precautions based on current guidance and the patient's symptoms.
How the assessment helps
For anesthesia and aspiration risk, a clinical intake can treat this as a triage signal, not a self-diagnosis shortcut. For the pre-operative window, the assessment helps organize weight history, waist and metabolic markers, medicines, glucagon-like peptide-1 safety factors, sleep concerns, red flags, and treatment fit so a clinician can decide what belongs in the plan.
Related reading:
References
[1] Jalleh RJ, Plummer MP, Marathe CS, et al. Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. J Clin Endocrinol Metab. 2024;110(1):1-15. doi:10.1210/clinem/dgae719 https://pubmed.ncbi.nlm.nih.gov/39418085/
[2] Sen S, Potnuru PP, Hernandez N, et al. Glucagon-Like Peptide-1 Receptor Agonist Use and Residual Gastric Content Before Anesthesia. JAMA Surg. 2024;159(6):660-667. doi:10.1001/jamasurg.2024.0111 https://pubmed.ncbi.nlm.nih.gov/38446466/
[3] American Society of Anesthesiologists. Most patients can continue GLP-1 drugs before surgery; those at highest risk need individualized plans. https://www.asahq.org/about-asa/newsroom/news-releases/2024/10/new-multi-society-glp-1-guidance
[4] American Society of Anesthesiologists consensus-based guidance on preoperative management of patients on GLP-1 receptor agonists. https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/american-society-of-anesthesiologists-consensus-based-guidance-on-preoperative
[5] DailyMed. WEGOVY semaglutide injection and tablet prescribing information, revised June 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
[6] DailyMed. ZEPBOUND tirzepatide injection prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b